The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
Jing Huang(Tianjin University of Traditional Chinese Medicine), Michael S. Goldberg(Jefferson Einstein Philadelphia Hospital), Ursula A. Matulonis(Dana-Farber Cancer Institute), Deyin Xing(Johns Hopkins Hospital), Zhongyi Cong(Jilin University), Sandra Oršulić(Cedars-Sinai Medical Center), Evgeny Kiner(Io Therapeutics (United States)), Lei Wang(Tang Hospital), Zohreh Amoozgar(Dana-Farber Cancer Institute)
Cited by 153
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
|Science|2018|1.5k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k